Stocks to sell

Reportedly, Biogen (NASDAQ:BIIB) and Japanese pharmaceutical company Eisai (OTCMKTS:ESALY) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB stock exploded higher on this news. However, these are early-stage results and prospective investors should read the fine print. Besides, if the good news has already been priced in, then buying now is tantamount

Nio (NYSE:NIO) has to deal with many of the same issues that other Chinese electric vehicle (EV) manufacturers do. For example, the company has to contend with supply-chain constraints and the challenge of sourcing lithium for EV batteries. On the other hand, an arrangement with a lithium producer may provide an advantage for Nio. That

What exactly does Ideanomics (NASDAQ:IDEX) stock represent? Is it an electric vehicle (EV) design company? Or a tractor producer? Maybe it’s trying to be a wireless charging provider this week? How about a maker of street sweepers? Frankly, it’s hard to pin this company down, and IDEX investors are understandably unimpressed with the company’s poor financial results.

As has been the case lately, investors are continuing to bail on Mullen Automotive (NASDAQ:MULN) stock. Just in the past month, shares in the fledgling electric vehicle (EV) maker are down around 50%. While you can blame market volatility for some of these price declines, the bulk of them are due to decreased confidence in

To investors bullish on SoFi Technologies (NASDAQ:SOFI) stock, the recent performance of its shares may seem irrational. In their view, the market is failing to factor in the potential tailwind stemming from the lifting of the student loan moratorium starting Jan. 1, 2023. After this happens, this fintech firm will supposedly benefit from a big

Headline inflation numbers continue to run near their highest levels in 40 years. The Federal Reserve hiked interest rates by 75 more basis points in September. Analysts are rightly nervous about how long this rising-price period will persist. However, one key sector of the economy is already signaling that the worst of the inflation has

As a sensible investor, the last thing you need is drama. Yet, there’s no shortage of it when it comes to electric vehicle (EV) startup Faraday Future (NASDAQ:FFIE) stock. The company is, as we’ll discover, in a capital-poor financial state. Granted, FFIE investors responded well when Faraday Future apparently managed to avoid a lawsuit from a

There’s a saying in investing, attributed to Warren Buffett, that you don’t see who’s swimming naked until the tide goes out.  Essentially, this means that poorly run and troubled companies are most exposed during market downturns. This is certainly proving to be the case this year. With all the major U.S. indices now in bear

The potential for high returns and stable income streams have made real estate investment trusts, or REITs, a popular investment vehicle. However, not all REITs are created equal, especially with a potential recession hanging overhead. On today’s list, I take a look at three REITs to sell. The reasoning for my bearishness on these particular

In general, when markets trend lower, it makes sense to invest in blue-chip stocks. They tend to have a low beta and also provide regular cash flows through dividends. Yet, not all blue chips are created equal. Based on macroeconomic or company-specific factors, there are some you want to buy and some blue-chip stocks to

Stocks to sell is a necessary discussion. Although it may feel good to remain loyal to an organization in the hopes of a substantial turnaround, it’s time to let go of some of the weaker entities. Fundamentally, the Federal Reserve plays an incredibly significant role in the red ink. With the central bank raising the

There’s no doubt about it: XPeng (NYSE:XPEV) wants the world to know that the company just unveiled a new SUV. That’s all fine and well, but was this event enough to assuage investors’ concerns about XPeng? So far, the answer is no. The Chinese automakers’ dwindling deliveries, along with macroeconomic issues, are legitimate issues and could

The Fed’s key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive. As a result, healthcare companies losing a great deal of money will have trouble obtaining new loans they can afford to pay off, and

It’s been a tumultous couple of years of real estate stocks. The pandemic caused unprecedented changes in people’s daily lives and working habits. Some categories of real estate investment trusts (REITs) benefitted from these adjustments. Sub-sectors such as data centers and industrial warehouses enjoyed a surge in demand during the pandemic period. Many categories of

This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equities market. Hence, investors are scrambling to streamline their portfolios. In doing so, they might want to

With stocks still in a bear market, adding dividend stocks may look very appealing right now. Even if the overall market keeps dropping, stocks with steady payouts could still produce positive returns for your portfolio. However, while there are opportunities out there for income-focused investors, there are also plenty of dividend stocks to sell if

This year, consumer stocks have been hammered as inflation lingers at 40-year highs and interest rates rise. The Dow Jones U.S. Consumer Goods Index is down 20% this year as consumers pull back on their spending. However, some consumer-focused companies have performed worse than others. Much worse.  Whether it is due to poor management, failure to adapt

Changing market conditions over the past year have had a severe impact on the performance of Luminar Technologies (NASDAQ:LAZR) stock. In 2020 and 2021, when investors were in “growth at any price” mode, shares in this provider of self-driving technology to the automotive industry were flying high. But with the shift in market sentiment about

Novavax (NASDAQ:NVAX) stock hasn’t had a great 2022, down 86% since the beginning of the year. The company focuses on products to treat infectious diseases but is definitely best known for its Covid-19 vaccine NVX-CoV2373, also known as Nuvaxovid. There are plenty of other competing vaccines in this category, and Novavax’s shots haven’t been strong sellers

There’s been some drama surrounding Cassava Sciences (NASDAQ:SAVA) recently. First, there was a report stating that the Securities and Exchange Commission, or SEC, cleared Cassava Sciences of charges of manipulating research results. Not long afterward, however, Cassava disputed the legitimacy of that report. These twists and turns in the ongoing story make it difficult to recommend